Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
Carcinoma of the lacrimal gland is a rare malignancy, limiting opportunities to develop new therapeutic regimens through clinical trials. There are no standard guidelines on optimal treatment of lacrimal gland carcinoma. In addition, lacrimal gland carcinoma includes several different subtypes with...
Saved in:
| Main Author: | Trevor Dennie |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2015/262357 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metastatic Osteosarcoma of Lacrimal Gland
by: Smitha K Shambhu, et al.
Published: (2017-07-01) -
Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use
by: C. García-Muñoz, et al.
Published: (2014-03-01) -
Zosteriform cutaneous metastases of HER-2 positive breast carcinoma resolved after treatment with lapatinib
by: Marcela Hernández-Coronado, et al.
Published: (2025-04-01) -
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
by: Justin Stebbing, et al.
Published: (2013-01-01) -
Advances in treatment of adenoid cystic carcinoma of the lacrimal gland
by: Jin-Bei Li, et al.
Published: (2025-08-01)